Key Insights

Highlights

Success Rate

83% trial completion

Published Results

49 trials with published results (23%)

Research Maturity

98 completed trials (47% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

9.6%

20 terminated out of 209 trials

Success Rate

83.1%

-3.5% vs benchmark

Late-Stage Pipeline

15%

31 trials in Phase 3/4

Results Transparency

50%

49 of 98 completed with results

Key Signals

49 with results83% success20 terminated

Data Visualizations

Phase Distribution

157Total
Not Applicable (37)
Early P 1 (9)
P 1 (16)
P 2 (64)
P 3 (24)
P 4 (7)

Trial Status

Completed98
Recruiting35
Active Not Recruiting21
Terminated20
Unknown16
Withdrawn10

Trial Success Rate

83.1%

Benchmark: 86.6%

Based on 98 completed trials

Clinical Trials (209)

Showing 20 of 20 trials
NCT05507125RecruitingPrimary

Regulation of Inflammatory Genes in Hidradenitis Suppurativa

NCT05403710RecruitingPrimary

Botulinum Toxin Therapy in Hidradenitis Suppurativa

NCT07049575Phase 1RecruitingPrimary

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT06046729Phase 2Active Not RecruitingPrimary

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT05889182Phase 3RecruitingPrimary

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT06374212Phase 2CompletedPrimary

Anifrolumab for Hidradenitis Suppurativa

NCT06921850Phase 3Active Not RecruitingPrimary

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT04901195Phase 3Active Not RecruitingPrimary

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06959225Phase 3Active Not RecruitingPrimary

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06801795Not ApplicableCompletedPrimary

Aviclear for Hidradenitis Suppurativa (HS)

NCT07454889Not Yet RecruitingPrimary

A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab

NCT07543419RecruitingPrimary

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

NCT05921994Active Not RecruitingPrimary

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

NCT06888193Phase 1Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT07708480Phase 4CompletedPrimary

Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis Suppurativa

NCT06468228Phase 3Active Not RecruitingPrimary

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07665437Phase 3RecruitingPrimary

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

NCT05243966Recruiting

Myriad™ Augmented Soft Tissue Reconstruction Registry

NCT07228390Phase 2RecruitingPrimary

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07690319Not Yet RecruitingPrimary

A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

Scroll to load more

Research Network

Activity Timeline